

1. Under Reviewed + Lampiran Hasil Review: Patterns of bronchodilator therapy in asthmatic outpatients

Gmail | Search: riska | Active | SMART UNIVERSITY

Journal of Public Health inAfrica: Decision on your manuscript

External | Inbox x

ICPHS 2022 <scicommicphs2022@gmail.com> | Jan 19, 2023, 3:40 PM

to me | Ref: Submission ID ICPHS-29

Dear Dr. Samirah,

Your manuscript, " Patterns of bronchodilator therapy in asthmatic outpatients ", has now been reviewed and the reviewer comments appended below. You will see that, while the reviewers find your work of interest, they have raised points that need to be addressed.

We therefore invite you to revise your paper, taking into account the points raised. At the same time, we ask you to make sure your manuscript complies with our format by reviewing our guidelines on preparing your manuscript as attached in this email. After revision, the manuscript should have a similarity index of less than 20%.

Once you have addressed each comment and completed each step listed below, the revised submission and final file can be uploaded via the link below.

<https://forms.gle/XoiHYyMZGkwwvbor5>

Gmail | Search: riska | Active | SMART UNIVERSITY

SUBMISSION REQUIREMENTS FOR REVISED PAPERS:

In order to process your paper, we require:

- A point-by-point response to the comments, including a description of any additional experiments that were carried out and a detailed rebuttal of any criticisms or requested revisions that you disagreed with.

This must be uploaded as a 'Point-by-point response to reviewers' file. All changes to the manuscript must be highlighted or indicated by using tracked changes.

At this stage, please also ensure that you have replaced your initial-submission image files with production quality figures. These should be supplied at 300 dpi resolution for .jpeg and .tiff or as .eps files. Figures should not include Figure number labels in the image.

Please ensure you conform to our authorship policies, also outlined here: <https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service.

Please note that your revised manuscript will be subject to another round of quality checking before it is returned to the Editor for assessment.

Please note we usually expect revisions to be returned within 14 days. If this doesn't apply to you, please request an extension by replying to this

Gmail | Search: riska | Active | SMART UNIVERSITY

Kind regards,

Tutik Sri Wahyuni
Andang Miatmoko


Guest Editors
Journal of Public Health in Africa (The thematic Issue of ICPHS 2022)

Reviewer Comments:

Reviewer 1
Please revise the manuscript as written in the reviewed file

Reviewer 2

1. Please use a separate page on tables and figures as the guideline
2. Please explain in the manuscript the reason for the inclusion criteria of the patients. (one year, three visits, and age 18-60)
3. In general, can the results obtained at RSUA be used as a role model of the use of bronchodilator drug therapy for asthma in other hospitals? Please write it in the discussion section.
4. Please write the novelty of the study



2. Lampiran Template Review: Patterns of bronchodilator therapy in asthmatic outpatients

1. Please use this template for all your revisions and add responses in the order they appear in the revision submitted
2. Add the reviewer comments followed by author response.
3. Make sure that the response is color coded to show a difference like below.
4. Please save this as a word file or in formats .DOC or .DOCX only
5. When submitting this template, you can remove these instructions.
6. For any questions please reach the journal manager at endmts@elsevier.com

Response to Reviewers

Title:

Manuscript number:

Revision Version: 1

Editor's Decision Received Date:

Revision Submission Date:

Author Response 1st revision

Reviewer 1

Reviewer Comments:

Author Response:

Reviewer 2

Reviewer Comments:

Author Response:

Title:

Manuscript number:

Revision Version: 2

Editor's Decision Received Date:

Revision Submission Date:

Author Response 2nd revision:

Reviewer 1

Reviewer Comments:

Author Response:

Reviewer 2

Reviewer Comments:

Author Response:

Title: Name of the Article

Manuscript number:

Revision Version: 3

Editor's Decision Received Date:

Revision Submission Date:

Author Response 3rd revision:

Reviewer 1

Reviewer Comments:

Author Response:

Reviewer 2

Reviewer Comments:

Author Response:

Patterns of bronchodilator therapy in asthmatic outpatients

Toetik Aryani¹, Riska Kholifatul Rahmawati², Ni Putu Cintyadewi³, Arina Dery Puspitasari¹, Alfian Nur Rasyid⁴ and Samirah^{1*}

¹Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

²Magister of Clinical Pharmacy Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya Indonesia

³Bachelor of Pharmacy Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

⁴Pulmonary Department, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Corresponding author : Samirah, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia
Phone +62315020514
Email samirah@ff.unair.ac.id

Acknowledgments : The author would like to thank Universitas Airlangga Hospital Surabaya

Keywords : Asthma, β 2 agonists, muscarinic antagonist, Inhaled corticosteroids

Authors' Contributions :

- Samirah: Substantial contributions to the conception or design research;
- Alvian Nur Rasyid : Consultant of pulmonary, interpretation of data asthmatic patients;
- Toetik Aryani: the acquisition, analysis data Patients;
- Riska Kholifatul Rahmawati: collecting data patients
- Ni Putu Cintyadewi: collecting data patients
- All author : Final approval of the version to be published.

Please write the author's contribution as the following:

Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation

Drafting the work or revising it critically for important intellectual content; AND

Final approval of the version to be published; AND

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

For example: N, JE: Substantial contributions to the conception or design of the work; N: the acquisition, analysis, or interpretation of data; JE: Drafting the work or revising it critically for important intellectual content; AND

All authors: Final approval of the version to be published

Abstract

Background: Bronchodilators are used to treat asthma symptoms. The administration of this therapy can be given through monotherapy or in combination to achieve the maximum therapeutic effect.

Objective: This study aimed to examine the prescribing pattern of bronchodilators in asthmatic outpatients

Methods: A retrospective study was done by reviewing and analyzing medical records of asthmatic outpatients from January 2019 until December 2020. Data analysis was performed descriptively.

Results: In this study, bronchodilators were administered by inhalation 97.4% compared to oral routes 2.6%. Combination bronchodilator therapy showed 54.7% compared to monotherapy by 46.3%. The combination ICS/LABA budesonide/formoterol 160/4.5 mcg was the most widely used (45.7%).

Conclusion: The use of a bronchodilator was in accordance with the Global Initiative for Asthma (GINA) guidelines. The route of drug administration through inhalation is more widely used than oral. Combination bronchodilators were more recommended than bronchodilator monotherapy.

Introduction

Asthma is a serious global health problem that occurs in all age groups. A survey showed that 300 million individuals worldwide suffer from asthma. The average prevalence is increasing in America, Europe, Africa, and Asia [1]. Specifically, the prevalence of asthma recurrence in all age groups in Indonesia reached (57.5%) in 2018 [2].

Asthma is generally characterized by chronic inflammation of the airways [3]. The goals of asthma treatment to improve symptom control, minimize the risk of exacerbations, reduce hospitalizations, prevent side effects from treatment, and achieve normal activities [4]. Inhaled corticosteroids (ICS) are effective as a therapy for controlling asthma symptoms. In uncontrolled conditions even with the use of medium doses of ICS, it is not appropriate to increase the dose of ICS because it can increase the risk of side effects. In addition, using low-dose ICS provides most of the clinical benefits. Rather than increasing the dose, it is necessary to add therapy with a combination to achieve an effective and safe treatment.

Bronchodilators such as β_2 agonists and muscarinic antagonists as add-ons to ICS can improve lung function, control symptoms, and reduce exacerbations [5]. β_2 agonist can be combined with ICS if the condition of asthma exacerbation is moderate or severe. Meanwhile, patients with mild asthma can be used β_2 agonist and low dose ICS combination when asthma exacerbations occur or before physical activity that can trigger worsening asthma symptoms [3]. Combination Low dose ICS/long-acting β_2 agonist (LABA) are recommended in improving control of symptoms well and preventing exacerbations. In addition, long-acting muscarinic antagonists can be used as adjunctive therapy when the combination of ICS and LABA does not control asthma symptoms well. Meanwhile, a combination short acting β_2 agonists (SABA) and ICS are prescribed for relieving symptoms during asthma exacerbations. [3] [5].

Bronchodilators widely used to treat asthma were selective β_2 agonist agents with an inhalation route of administration. The Advantage of the inhalation route of administration is increase the local effect on the smooth muscle of the airway nerves and minimizes the risk of side effects [8]. Selection of the type of bronchodilator and route of administration needs to consider the patient's condition to improve the quality of pharmaceutical care and achieve the maximum therapeutic effect. Therefore, this study examines the prescribing pattern of bronchodilators in asthmatic outpatients.

Material and Method

This study used retrospective observation as a research method. It used medical record data of asthmatic outpatients **please use an appropriate term** in the Pulmonary Poly. The samples in this study were all medical record data of stable asthmatic outpatients with bronchodilator therapy at Universitas Airlangga Hospital within 1 year of monitoring therapy from January 2019 until December 2020 period. The research protocols of this study submitted to the Ethics and Law Committee were approved with a certificate number of ethics approval: 140/KEP/2021.

the inclusion criteria should be medical record data Patients who met the inclusion criteria were patients aged 18-60 years who had asthma without another comorbid respiratory tract disease and completed at least three visits in one year. While the exclusion criteria of the respondents were asthmatic outpatients whose medical record data were incomplete, including therapy data for patients who did not receive bronchodilators during one-year therapy monitoring. Data was carried out using a time-limited sampling technique.

Eligible medical record data of asthma patients who received bronchodilator therapy from January 2019 until December 2020 were selected. The next step was collecting necessary information from the medical records, such as patient identity, clinical data, laboratory data, and profile of bronchodilator used i.e type of bronchodilator, route of administration, and dosage regiment. Data were processed **and recapitulated** and finally analyzed descriptively. **inappropriate term**

Result

please explain the data

This study included 73 patients were demographic characteristics are shown in **Table 1**. The route of administration through inhalation is the more widely given (97.4%) compared to oral routes (2.6%) shown in **Figure 1**. Meanwhile, combination bronchodilator therapy showed (54.7%) compared to bronchodilator monotherapy (46.3%) shown in **Figure 2**. The pattern of bronchodilators is shown **Table 2**. Each patient could receive more than **how it can be explained? is there any data of therapy adjustment history? if yes, it is also should be presented** one type of bronchodilator **when symptoms were not resolved with monotherapy**. Some patients have changes in therapy such as decreasing or increasing the frequency of drug administration depending on the evaluation of therapy for each visit. The combination ICS/LABA budesonide/formoterol 160/4.5 mcg was the most widely used (45.7%). **The frequency of the combination bronchodilators varies according to the severity of asthma**. In this study, the frequency of budesonide/formoterol 1 inhalation two times daily was the most widely given (32.8%). Meanwhile, another ICS/LABA combination used was **it should be further explain about the asthma severity and according to the study, the drugs used should be classified too**

fluticasone propionate/salmeterol 250/50 mcg (3.1%). While bronchodilator monotherapy widely used was a SABA fenoterol Hbr dose of 100 mcg (30.7%). The frequency of fenoterol HBr 100 mcg 1 inhalation daily was the most prescribed (10.4%).

Discussion

Table 1 shows the prevalence of asthma was greater in females (80.80%) than in males (19.20%). This finding suggests asthma is related to sex factors. In adults, the prevalence of asthma is higher in females than in males. Ovarian hormones such as estrogen and progesterone increase inflammation in asthmatic patients, while androgens such as testosterone and 5- α dihydrotestosterone reduce inflammation by suppressing innate and adaptive immune system responses [6]. The prevalence of asthma was higher (41.1%) in the age of 48-57 years. The adult, asthma is often caused by exposure to pollutants, cigarette smoke, obesity, and respiratory infections [9]. Additionally, this study showed that 76.7% of asthmatic patients had **unknown comorbidities** because they were not listed in the medical records. Such absence of data is a limitation of this retrospective study. The prevalence of comorbid hypertension among the outpatients was 13.7%, higher than other comorbidities. Based on pathophysiology, no relationship was found between hypertension and asthma. However, the use of nonselective beta-adrenergic blockers can trigger asthma exacerbations [10].

In figure 1 bronchodilators are more administered by inhalation (97.4%) compared to oral routes (2.6%). Inhalation routes provide faster onset of action, the greatest local effect on the smooth muscle of the respiratory tract, fewer side effects, and small doses that are more effective than the oral routes [8]. In this study, some patients still received oral drugs with various possibilities. For example, 1) inhaled dosage forms are not available; 2) inhalation preparations are more expensive; 3) oral dosage forms are easier to use; 4) administering drugs through oral routes more likely reduces a social stigma than through inhalation; 5) most patients still have lack of knowledge regarding inhalation method; 6) in addition, oral preparations can be used in a shorter period.

Combination bronchodilator therapy showed 54.7% compared to monotherapy by 46.3% in **Figure 2**. Combination more than one bronchodilator in one device provides convenience, improving compliance with patients, and minimizing the risk of side effects [25]. **Table 2** shows the combination of budesonide/formoterol 160/4.5 mcg was the most widely used combination of ICS and long-acting β_2 agonist (45.7%). The frequency of the

combination budesonide/formoterol 160/4.5 mcg varies according to the severity of asthma. In this study, the frequency of budesonide/formoterol 1 inhalation two times daily was the most widely given (32.8%). Another ICS/LABA combination used was fluticasone propionate/salmeterol 250/50 mcg (3.1%). Previous research found the combination of fluticasone propionate/salmeterol had the same response as the combination of budesonide/formoterol to improve lung function, and both therapies had no difference in the side effects [11]. Long-acting β 2 agonist (LABA) formoterol has a rapid onset of action (1-3 minutes after inhalation) with a long duration of action (> 12 hours after inhalation) [12]. Rapid onset LABA formoterol is as effective as short-acting β 2 agonist (SABA) as a reliever, and LABA is more effective than regular SABA.

For patients taking SABA and requiring corticosteroids, repeated use of SABA may relieve symptoms temporarily, but giving SABA as a reliever was not more effective in preventing exacerbation severity than a low-dose combination of ICS/LABA [3]. However, regular use of LABA or SABA potentially decreases the sensitivity of bronchodilators to β agonist or induces tolerance of their bronchoprotective effect, thereby increasing the risk of exacerbations [3] [13].

Using regular LABA or SABA without ICS is not recommended because increases the risk of exacerbation. However, the ICS/LABA combination is effective in improving patient compliance, preventing exacerbations, control of symptoms well, and reducing ICS doses [3]. Additionally, ICS/LABA combination is more able to reduce the incidence of withdrawal lower than ICS monotherapy [14] [24]. The role of β 2 agonists is vasodilation of the respiratory tract, inhibit the proliferation of respiratory smooth muscles, and become an anti-inflammatory agent [15].

Short-acting muscarinic antagonist (SAMA) is an alternative therapy to SABA for reducing asthma symptoms [3]. The combination of SABA/SAMA given to asthmatic outpatients was Ipratropium bromide/salbutamol 0,5/2,5 mg amounted to (5,7%). SAMA shows lower effectiveness in providing bronchodilation effects on acute asthmatic patients than SABA [16]. Moreover, SAMA like ipratropium has a slower onset of action than SABA [3]. A clinical study showed that SAMA significantly improved bronchodilation, but it did not improve lung function [17]. However, for adult and paediatric asthmatic patients who had moderate to severe exacerbations. The combination of SABA/SAMA is more likely could improve the peak expiratory flow (PEF) compared to SABA alone. In addition, this therapy is associated with a lower incidence of hospitalization [3].

While bronchodilator monotherapy widely used for asthmatic outpatients was a SABA fenoterol Hbr dose of 100 mcg (30.7%) followed by SABA salbutamol 2,5 mg inhalations (4.7%). The dose of salbutamol and frequency of the drug administration varied based on the clinical conditions of the patients. Another type of bronchodilator monotherapy used was the muscarinic antagonist including a Long-acting muscarinic antagonist (LAMA) tiotropium bromide dose of 2,5 mcg given once a day (1,0%). Muscarinic antagonists reduce eosinophils, inhibit the remodelling and thickening of airway smooth muscle [18]. LAMA was an alternative therapy to control asthma as it can optimize lung function and prevent exacerbations better than LABA [5]. Besides, it can be used as adjunctive therapy when the combination of ICS/LABA does not control asthma symptoms well [3]. However, LAMA monotherapy without ICS may increase the risk of exacerbations [19] [21]. Several studies have stated that patients who are given LABA in combination with ICS still experience exacerbated symptoms, and thus it is important to consider using a minimally moderate dose of ICS in combination with LABA before adding LAMA [3] [23].

Other bronchodilators such as methylxanthines (e.g., theophylline and aminophylline) are no longer used for the asthmatic outpatients in this study. Following GINA guidelines, the administration of methylxanthines is not recommended for the management of exacerbated asthma in that methylxanthines have a low safety profile and poor efficacy. Additionally, it has a narrow therapeutic index when it interacts with other drugs. One of the potentially fatal side effects caused by methylxanthines is cardiovascular disorders such as arrhythmia [7]. While compared to SABA, the effectiveness and safety of SABA are better than methylxanthine [3].

Conclusion

Bronchodilators as asthma therapy were used according to the GINA guidelines. The route of drug administration through inhalation more widely used than oral. Combination bronchodilators were more recommended than bronchodilator monotherapy. The combination of ICS/LABA is the first line to improve lung function, control symptoms, and reduce asthma exacerbations

References

- [1] Kawamatawong T, Sangasapaviriya A, Saiphoklang N, Oer-Areemitr N, Sriprasa T, Kamalporn H, et al. Guidelines for the management of asthma in adults:

- Evidence and recommendations. Vol. 40, Asian Pacific Journal of Allergy and Immunology. Allergy and Immunology Society of Thailand; 2022. p. 1–21
- [2] Basic health research. RISKESDAS national report. Balitbangkes publishing agency. 2018.
- [3] Global initiative for asthma (GINA). Global strategy for asthma Management and Prevention. Global Initiative for Asthma. 2022.
- [4] Dusser D, Ducharme FM. Safety of tiotropium in patients with asthma. Vol. 13, Therapeutic Advances in Respiratory Disease. SAGE Publications Ltd; 2019.
- [5] Kaplan A, FitzGerald JM, Buhl R, Vogelberg C, Hamelmann E. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. Vol. 30, npj Primary Care Respiratory Medicine. Nature Research; 2020.
- [6] Fuseini H, Newcomb DC. Mechanisms Driving Gender Differences in Asthma. Vol. 17, Current Allergy and Asthma Reports. Current Medicine Group LLC 1; 2017.
- [7] Klimovic S, Scurek M, Pesl M, Beckerova D, Jelinkova S, Urban T, et al. Aminophylline Induces Two Types of Arrhythmic Events in Human Pluripotent Stem Cell–Derived Cardiomyocytes. *Front Pharmacol.* 2022 Jan 17;12
- [8] Silva D, Jacinto T. Inhaled β 2-agonists in asthma management: An evolving story. *Breathe.* 2016;12(4):379–81.
- [9] de Boer GM, Tramper-Stranders GA, Houweling L, van Zelst CM, Pouw N, Verhoeven GT, et al. Adult but not childhood onset asthma is associated with the metabolic syndrome, independent from body mass index. *Respir Med.* 2021 Nov 1;188.
- [10] Christiansen SC, Zuraw BL. Treatment of Hypertension in Patients with Asthma. *New England Journal of Medicine.* 2019 Sep 12;381(11):1046–57.
- [11] Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. *Respir Med.* 2007;101(12):2437–46.
- [12] Heo YA. Budesonide/Glycopyrronium/Formoterol: A Review in COPD. Vol. 81, *Drugs.* Adis; 2021. p. 1411–22.
- [13] Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R. Safety of long-acting β -agonists: Urgent need to clear the air remains. Vol. 33, *European Respiratory Journal.* 2009. p. 3–5.

- [14] Patel S, Dickinson S, Morris K, Ashdown HF, Chalmers JD. A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients. *NPJ Prim Care Respir Med*. 2022 Dec 1;32(1)..
- [15] Billington CK, Penn RB, Hall IP. β_2 Agonists. In: *Handbook of Experimental Pharmacology*. Springer New York LLC; 2016. p. 23–40.
- [16] Radovanovic D, Santus P, Blasi F, Mantero M. The evidence on tiotropium bromide in asthma: From the rationale to the bedside. Vol. 12, *Multidisciplinary Respiratory Medicine*. BioMed Central Ltd; 2017.
- [17] Montuschi P, Ciabattini G. Bronchodilating drugs for chronic obstructive pulmonary disease: Current status and future trends. Vol. 58, *Journal of Medicinal Chemistry*. American Chemical Society; 2015. p. 4131–64.
- [18] Halpin DMG. Tiotropium in asthma: What is the evidence and how does it fit in? Vol. 9, *World Allergy Organization Journal*. BioMed Central Ltd; 2016.
- [19] Baan EJ, Hoeve CE, de Ridder M, Demoen L, Lahousse L, Brusselle GG, et al. The ALPACA study: (In)Appropriate LAMA prescribing in asthma: A cohort analysis. *Pulm Pharmacol Ther*. 2021.1;71.
- [20] Marques L, Vale N. Salbutamol in the Management of Asthma: A Review. Vol. 23, *International journal of molecular sciences*. NLM (Medline); 2022.
- [21] Barjaktarevic I, Kaner R, Buhr RG, Cooper CB. Bronchodilator responsiveness or reversibility in asthma and COPD - A need for clarity. Vol. 13, *International Journal of COPD*. Dove Medical Press Ltd.; 2018. p. 3511–3.
- [22] Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. *Pharmacol Rev*. 2020 Jan 1;72(1):218–52.
- [23] Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Vol. 77, *Allergy: European Journal of Allergy and Clinical Immunology*. John Wiley and Sons Inc; 2022. p. 1105–13.
- [24] Singh D, Garcia G, Maneechotesuwan K, Daley-Yates P, Irusen E, Aggarwal B, et al. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management. Vol. 39, *Advances in Therapy*. Adis; 2022. p. 1895–914.
- [25] Papi A. A new combination therapy for asthma: Bridging the gap between effectiveness in trials and clinical practice? *Respir Med*. 2012;106

Tables and Figures

Table 1: Demographic characteristics

Characteristics		n (%)
Sex	Male	14 (19.20)
	Female	59 (80.80)
Age	18-27	12 (16.4)
	28-37	7 (9.6)
	38-47	19 (26.0)
	48-57	30 (41.1)
	58-60	5 (6.8)
Comorbid	No Comorbid	56 (76.7)
	Hypertension	10 (13.7)
	Dyslipidemia + Diabetes mellitus	2 (2.7)
	Diabetes mellitus	1 (1.4)
	Hypertension + Diabetes mellitus	1 (1.4)
	Dyslipidemia + Diabetes mellitus + Hypertension	1 (1.4)
	Hypertension + Coronary heart disease	1 (1.4)
	Gastroesophageal reflux disease	no data information

Figure 1 Prevalence of drug administration routes




Figure 2 Prevalence receiving monotherapy or combination therapy




Table 2 : Pattern of Bronchodilators in Ashmathic Outpatients

Drug	Dosage	n (%)	Total receiving bronchodilators n(%)
β2 agonists			
SABA Salbutamol 2,5 mg inhalation	-	9 (4.7)	9 (4.7)
Salbutamol 100 mcg inhalation	100 mcg daily or 1 inhalation daily	2 (1.0)	4 (3.0)
	200 mcg daily or 2 inhalations daily	1 (0.5)	
	100 mcg or 1 inhalation, 2 times daily	1 (0.5)	
	100 mcg or 1 inhalation, 3 times daily	2 (1.0)	
Salbutamol 2 mg oral	2 mg 2 times daily	2 (1.0)	4 (3.0)
	2 mg 2 times daily	1 (1.0)	
	2 mg 3 times daily	1 (1.0)	
Salbutamol 4 mg oral	4 mg 2 times daily	1 (0.5)	1 (0.5)
Fenoterol HBr 100 mcg inhalation	100 mcg or 1 inhalation daily	20 (10.4)	59 (30.7)
	200 mcg or 2 inhalations daily	7 (3.6)	
	100 mcg or 1 inhalation, 2 times daily	14 (7.3)	
	200 mcg or 2 inhalations, 2 times daily	3 (1.6)	
	100 mcg or 1 inhalation, 3 times daily	15 (7.8)	
LABA Procaterol HCl 50 mcg inhalation	-	4 (2.1)	4 (2.1)
Ultra LABA Indacaterol 150 mcg inhalation	150 mcg daily	2 (1.0)	2 (1.0)
Muscarinic Antagonist			
LAMA Tiotropium Bromide 2.5 mcg inhalation	2,5 mcg daily	2 (1.0)	2 (1.0)
Combination			
ICS/LABA Budesonide/Formoterol (160/4.5 mcg) inhalations	1 inhalation daily	16 (8.3)	88 (45.7)
	2 inhalations daily	1 (0.5)	
	1 inhalation, 2 times daily	63 (32.8)	
	2 inhalations, 2 times daily	7 (3.6)	
	1 inhalation, 3 times daily	1 (0.5)	
SAMA/SABA Ipratropium Bromide/Salbutamol (0.5/2.5 mg) inhalations	-	11 (5.7)	11 (5.7)
ICS/LABA Fluticasone Propionate/Salmeterol (250/50 mcg) inhalations	1 inhalation, 2 times daily	5 (2.6)	6 (3.1)
	1 inhalation, 1 times daily	1 (0.5)	

3. Lampiran Hasil Perbaikan Author: Patterns of bronchodilator therapy in asthmatic outpatients

Patterns of bronchodilator therapy in asthmatic outpatients

Toetik Aryani¹, Riska Kholifatul Rahmawati², Ni Putu Cintyadewi³, Arina Dery Puspitasari¹, Alfian Nur Rasyid⁴ and Samirah^{1*}

¹Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

²Magister of Clinical Pharmacy Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya Indonesia

³Bachelor of Pharmacy Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

⁴Pulmonary Department, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Corresponding author : Samirah, Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia
Phone +62315020514
Email samirah@ff.unair.ac.id

Acknowledgments : The author would like to thank Universitas Airlangga Hospital Surabaya

Keywords : Asthma, β 2 agonists, muscarinic antagonist, Inhaled corticosteroids

Authors' Contributions :

- Samirah: Substantial contributions to the conception or design research;
- Alvian Nur Rasyid : Consultant of pulmonary, interpretation of data asthmatic patients;
- Toetik Aryani: the acquisition, analysis data Patients;
- Riska Kholifatul Rahmawati: collecting data patients
- Ni Putu Cintyadewi: collecting data patients
- All authors: Final approval of the version to be published, drafting the research or revising it critically for important intellectual content, and agreement to be accountable for all aspects of the research in ensuring that questions related to the accuracy or integrity of any part of the research are appropriately investigated and resolved.

Abstract

Background: Bronchodilators are used to treat asthma symptoms. The administration of this therapy can be given through monotherapy or in combination to achieve the maximum therapeutic effect.

Objective: This study aimed to examine the prescribing pattern of bronchodilators in asthmatic outpatients

Methods: A retrospective study was done by reviewing and analyzing medical records of asthmatic outpatients from January 2019 until December 2020. Data analysis was performed descriptively.

Results: In this study, bronchodilators were administered by inhalation 97.4% compared to oral routes 2.6%. Combination bronchodilator therapy showed 54.7% compared to monotherapy by 46.3%. The combination ICS/LABA budesonide/formoterol 160/4.5 mcg was the most widely used 45.7%.

Conclusion: The use of a bronchodilator was in accordance with the Global Initiative for Asthma (GINA) guidelines. The route of drug administration through inhalation is more widely used than oral. Combination bronchodilators were more recommended than bronchodilator monotherapy to control asthma symptoms.

Introduction

Asthma is a serious global health problem that occurs in all age groups. A survey showed that 300 million individuals worldwide suffer from asthma. The average prevalence is increasing in America, Europe, Africa, and Asia [1]. Specifically, the prevalence of asthma recurrence in all age groups in Indonesia reached (57.5%) in 2018 [2].

Asthma is generally characterized by chronic inflammation of the airways. GINA guidelines classify asthma severity i.e mild, moderate, and severe based on controller treatment for several months. Mild defined asthma was well controlled with low dose ICS/LABA, moderate when asthma was well controlled with low or medium dose ICS/LABA, severe where asthma remains uncontrolled despite using high dose ICS/LABA or requires high dose ICS/LABA to prevent uncontrolled asthma [3]. The goals of asthma treatment to improve symptoms control, minimize the risk of exacerbations, reduce hospitalizations, prevent side effects from treatment, and achieve normal activities [4]. Inhaled corticosteroids (ICS) are effective as a therapy for controlling asthma symptoms. In uncontrolled conditions even with the use of medium doses of ICS, it is not appropriate to increase the dose of ICS because it can increase the risk of side effects. In addition, using low-dose ICS provides most of the clinical benefits. Rather than increasing the dose, it is necessary to add therapy with a combination to achieve an effective and safe treatment.

Bronchodilators such as β_2 agonists and muscarinic antagonists as add-ons to ICS can improve lung function, control symptoms, and reduce exacerbations [5]. β_2 agonist can be combined with ICS if the condition of asthma exacerbation is moderate or severe. Meanwhile, patients with mild asthma can be used β_2 agonist and low dose ICS combination when asthma exacerbations occur or before physical activity that can trigger worsening asthma symptoms [3]. Combination Low dose ICS/long-acting β_2 agonist (LABA) are recommended in improving control of symptoms well and preventing exacerbations. In addition, long-acting muscarinic antagonists can be used as adjunctive therapy when the combination of ICS and LABA does not control asthma symptoms well. Meanwhile, a combination short acting β_2 agonists (SABA) and ICS are prescribed for relieving symptoms during asthma exacerbations. [3] [5].

Bronchodilators widely used to treat asthma were selective β_2 agonist agents with an inhalation route of administration. The Advantage of the inhalation route of administration is increase the local effect on the smooth muscle of the airway nerves and minimizes the risk of side effects [8]. Selection of the type of bronchodilator and route of administration needs to consider the patient's condition to improve the quality of pharmaceutical care and achieve the

maximum therapeutic effect. Therefore, this study examines the prescribing pattern of bronchodilators in asthmatic outpatients.

Material and Method

This study used retrospective observation as a research method. It used medical record data of asthmatic outpatients in the pulmonary unit. The samples in this study were all medical record data of stable asthmatic outpatients with bronchodilator therapy at Universitas Airlangga Hospital within 1 year of monitoring therapy from January 2019 until December 2020 period. The research protocols of this study submitted to the Ethics and Law Committee were approved with a certificate number of ethics approval: 140/KEP/2021.

The inclusion criteria in this study were the patient's medical record showed the age 18-60 years who had asthma without another comorbid respiratory tract disease and completed at least three visits in one year. Based on data from the Centers for Disease and Asthma Prevention (2019), the prevalence of asthma patients occurs mostly in adults over 18 years old, then to determine the effectiveness of bronchodilators on asthma symptoms control for several months, patients were monitored within 1 year with a minimum of 3 visits. While the exclusion criteria were the patient's medical record data were incomplete, including therapy data for patients who did not receive bronchodilators during one-year therapy monitoring. Data was carried out using a time-limited sampling technique. The number of samples taken in this study obtained was 73 patients.

Eligible medical record data of asthma patients who received bronchodilator therapy from January 2019 until December 2020 were selected. The next step was collecting necessary information from the medical records, such as patient identity, clinical data, laboratory data, and profile of bronchodilator used i.e type of bronchodilator, route of administration, and dosage regiment. The results were analysed descriptively using frequency and percentage.

Result

Table 1 shows the prevalence of asthma was greater in females (80.80%) than in males (19.20%). The prevalence of asthma was higher (41.1%) in the age of 48-57 years. Additionally, this study showed that (76.7%) of asthmatic patients had unknown comorbidities. Meanwhile, asthma patients on bronchodilator therapy do not have any symptoms (41.4%) and (58.6%) still had asthma symptoms such as coughing tightness, chest pain, and shortness of breath. The route of administration through inhalation is the more widely given

(97.4%) compared to oral routes (2.6%) shown in **Figure 1**. Meanwhile, combination bronchodilator therapy showed (54.7%) compared to bronchodilator monotherapy (46.3%) shown in **Figure 2**.

Table 2 shows the total number of drugs received by 73 asthma patients is 192 drugs because each patient can receive more than one type of bronchodilator drug because the patients get additional therapy when symptoms are not resolved with monotherapy. Some patients have changes in therapy such as decreasing or increasing the frequency of drug administration depending on the evaluation of therapy for each visit. The combination ICS/LABA budesonide/formoterol 160/4.5 mcg was the most widely used (45.7%). In this study, the frequency of budesonide/formoterol 1 inhalation two times daily was the most widely given (32.8%). Meanwhile, another ICS/LABA combination used was fluticasone propionate/salmeterol 250/50 mcg (3.1%). While bronchodilator monotherapy widely used was a SABA fenoterol Hbr dose of 100 mcg (30.7%). The frequency of fenoterol HBr 100 mcg 1 inhalation daily was the most prescribed (10.4%). **The results obtained in this study were the types of bronchodilator therapy patterns in all outpatients with asthma without distinguishing the severity level.**

Discussion

Table 1 shows the prevalence of asthma was greater in females (80.80%) than in males (19.20%). This finding suggests asthma is related to sex factors. In adults, the prevalence of asthma is higher in females than in males. Ovarian hormones such as estrogen and progesterone increase inflammation in asthmatic patients, while androgens such as testosterone and 5- α dihydrotestosterone reduce inflammation by suppressing innate and adaptive immune system responses [6]. The prevalence of asthma was higher (41.1%) in the age of 48-57 years. The adult, asthma is often caused by exposure to pollutants, cigarette smoke, obesity, and respiratory infections [9]. Additionally, this study showed that 76.7% of asthmatic patients had unknown comorbidities because they were not listed in the medical records. Such absence of data is a limitation of this retrospective study. The prevalence of comorbid hypertension among the outpatients was 13.7%, higher than other comorbidities. Based on pathophysiology, no relationship was found between hypertension and asthma. However, the use of nonselective beta-adrenergic blockers can trigger asthma exacerbations [10]. **Good asthma symptoms control status is the goal of therapy i.e reduced or no asthma symptoms, normal activity, no sleep disturbances due to asthma, and optimal**

lung function [3]. In this study, asthma patients on bronchodilator therapy do not have any symptoms (41.4%), meanwhile (58.6%) still had asthma symptoms such as coughing and shortness of breath. Patients who had no symptoms indicate the therapy is appropriate to control asthma patients. Some of the possibilities for patients having poor asthma control can be related to drug side effects from therapies other than bronchodilators, obesity, lack of physical activity, exposure to allergens or asthma triggers, and lack of emotional control [3]. Additionally, based on the result patients with poor symptoms of asthma such as coughing, tightness, and chest pain were experienced by patients with comorbid coronary heart disease, where the chest pain is one of the symptoms of coronary heart disease [26].

In **figure 1** bronchodilators are more administered by inhalation (97.4%) compared to oral routes (2.6%). Inhalation routes provide faster onset of action, the greatest local effect on the smooth muscle of the respiratory tract, fewer side effects, and small doses that are more effective than the oral routes [8]. In this study, some patients still received oral drugs with various possibilities. For example, 1) inhaled dosage forms are not available; 2) inhalation preparations are more expensive; 3) oral dosage forms are easier to use; 4) administering drugs through oral routes more likely reduces a social stigma than through inhalation; 5) most patients still have lack of knowledge regarding inhalation method; 6) in addition, oral preparations can be used in a shorter period.

Combination bronchodilator therapy showed 54.7% compared to monotherapy by 46.3% in **Figure 2**. Combination more than one bronchodilator in one device provides convenience, improving compliance patients, and minimizing the risk of side effects [25]. **Table 2** shows the combination of budesonide/formoterol 160/4.5 mcg was the most widely used combination of ICS and long-acting β_2 agonist (45.7%). The frequency of the combination budesonide/formoterol 160/4.5 mcg varies according to the severity of asthma. In this study, the frequency of budesonide/formoterol 1 inhalation two times daily was the most widely given (32.8%). Another ICS/LABA combination used was fluticasone propionate/salmeterol 250/50 mcg (3.1%). **Research by Bousquet** et al found the combination of fluticasone propionate/salmeterol had the same response as the combination of budesonide/formoterol to improve lung function, and both therapies had no difference in the side effects [11]. Long-acting β_2 agonist (LABA) formoterol has a rapid onset of action (1-3 minutes after inhalation) with a long duration of action (> 12 hours after inhalation) [12]. Rapid onset LABA formoterol is as effective as short-acting β_2 agonist (SABA) as a reliever, and LABA is more effective than regular SABA.

For patients taking SABA and requiring corticosteroids, repeated use of SABA may relieve symptoms temporarily, but giving SABA as a reliever was not more effective in preventing exacerbation than a low-dose combination of ICS/LABA [3]. However, regular use of LABA or SABA potentially decreases the sensitivity of bronchodilators to β agonist or induces tolerance of their bronchoprotective effect, thereby increasing the risk of exacerbations [3] [13].

Using regular LABA or SABA without ICS is not recommended because increases the risk of exacerbation. However, the ICS/LABA combination is effective in improving patient compliance, preventing exacerbations, control of symptoms well, and reducing ICS doses [3]. Additionally, ICS/LABA combination is more able to reduce the incidence of withdrawal lower than ICS monotherapy [14] [24]. The role of β_2 agonists is vasodilation of the respiratory tract, inhibit the proliferation of respiratory smooth muscles, and become an anti-inflammatory agent [15].

Short-acting muscarinic antagonist (SAMA) is an alternative therapy to SABA for reducing asthma symptoms [3]. The combination of SABA/SAMA given to asthmatic outpatients was Ipratropium bromide/salbutamol 0,5/2,5 mg amounted to (5,7%). SAMA shows lower effectiveness in providing bronchodilation effects on acute asthmatic patients than SABA [16]. Moreover, SAMA like ipratropium has a slower onset of action than SABA [3]. A clinical study showed that SAMA significantly improved bronchodilation, but it did not improve lung function [17]. However, for adult and paediatric asthmatic patients who had moderate to severe exacerbations. The combination of SABA/SAMA is more likely could improve the peak expiratory flow (PEF) compared to SABA alone. In addition, this therapy is associated with a lower incidence of hospitalization [3]. Research by Donohue et al showed that the use of a combination of ipratropium bromide/salbutamol provides a better bronchodilation effect and has significantly different in patients with moderate-severe asthma compared to a single salbutamol [27].

While bronchodilator monotherapy widely used for asthmatic outpatients was a SABA fenoterol Hbr dose of 100 mcg (30.7%) followed by SABA salbutamol 2,5 mg inhalations (4.7%). The dose of salbutamol and frequency of the drug administration varied based on the clinical conditions of the patients. Another type of bronchodilator monotherapy used was the muscarinic antagonist including a Long-acting muscarinic antagonist (LAMA) tiotropium bromide dose of 2,5 mcg given once a day (1,0%). Muscarinic antagonists reduce eosinophils, inhibit the remodelling and thickening of airway smooth muscle [18]. LAMA was an alternative therapy to control asthma as it can optimize lung function and prevent

exacerbations better than LABA [5]. Besides, it can be used as adjunctive therapy when the combination of ICS/LABA does not control asthma symptoms well [3]. However, LAMA monotherapy without ICS may increase the risk of exacerbations [19] [21]. Several studies have stated that patients who are given LABA in combination with ICS still experience exacerbated symptoms, and thus it is important to consider using a minimally moderate dose of ICS in combination with LABA before adding LAMA [3] [23]. Research by Ullah et al showed that the addition of tiotropium in combination ICS/LABA had a significant difference in improving lung function in patients with severe persistent asthma [28].

Other bronchodilators such as methylxanthines (e.g., theophylline and aminophylline) are no longer used for the asthmatic outpatients in this study. Following GINA guidelines, the administration of methylxanthines is not recommended for the management of exacerbated asthma in that methylxanthines have a low safety profile and poor efficacy. Additionally, it has a narrow therapeutic index when it interacts with other drugs. One of the potentially fatal side effects caused by methylxanthines is cardiovascular disorders such as arrhythmia [7]. While compared to SABA, the effectiveness and safety of SABA are better than methylxanthine [3]. Research by Lorensia et al showed the incidence of side effects in the use of intravenous aminophylline was very rare and was not even found in several hospital patients in Surabaya [29].

The results of this study can be used to improve the quality of health services especially in guiding the management of asthma therapy in other hospitals due to combination bronchodilators can improve compliance among patients and minimize the risk of side effects, while inhalation routes bronchodilators provide faster onset of action, the greatest local effect on the smooth muscle of the respiratory tract, fewer side effects, and small doses that are more effective than the oral routes.

Conclusion

Bronchodilators as asthma therapy were used according to the GINA guidelines. The route of drug administration through inhalation more widely used than oral. Combination bronchodilators were more recommended than bronchodilator monotherapy. The combination of ICS/LABA is the first line to improve lung function, control symptoms, and reduce asthma exacerbations.

References

- [1] Kawamatawong T, Sangasapaviriya A, Saiphoklang N, Oer-Areemitr N, Sriprasa T, Kamalaporn H, et al. Guidelines for the management of asthma in adults: Evidence and recommendations. Vol. 40, *Asian Pacific Journal of Allergy and Immunology*. Allergy and Immunology Society of Thailand; 2022. p. 1–21
- [2] Basic health research. RISKESDAS national report. Balitbangkes publishing agency. 2018.
- [3] Global initiative for asthma (GINA). Global strategy for asthma Management and Prevention. Global Initiative for Asthma. 2022.
- [4] Dusser D, Ducharme FM. Safety of tiotropium in patients with asthma. Vol. 13, *Therapeutic Advances in Respiratory Disease*. SAGE Publications Ltd; 2019.
- [5] Kaplan A, FitzGerald JM, Buhl R, Vogelberg C, Hamelmann E. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. Vol. 30, *npj Primary Care Respiratory Medicine*. Nature Research; 2020.
- [6] Fuseini H, Newcomb DC. Mechanisms Driving Gender Differences in Asthma. Vol. 17, *Current Allergy and Asthma Reports*. Current Medicine Group LLC 1; 2017.
- [7] Klimovic S, Scurek M, Pesl M, Beckerova D, Jelinkova S, Urban T, et al. Aminophylline Induces Two Types of Arrhythmic Events in Human Pluripotent Stem Cell–Derived Cardiomyocytes. *Front Pharmacol*. 2022 Jan 17;12
- [8] Silva D, Jacinto T. Inhaled β 2-agonists in asthma management: An evolving story. *Breathe*. 2016;12(4):379–81.
- [9] de Boer GM, Tramper-Stranders GA, Houweling L, van Zelst CM, Pouw N, Verhoeven GT, et al. Adult but not childhood onset asthma is associated with the metabolic syndrome, independent from body mass index. *Respir Med*. 2021 Nov 1;188.
- [10] Christiansen SC, Zuraw BL. Treatment of Hypertension in Patients with Asthma. *New England Journal of Medicine*. 2019 Sep 12;381(11):1046–57.
- [11] Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. *Respir Med*. 2007;101(12):2437–46.
- [12] Heo YA. Budesonide/Glycopyrronium/Formoterol: A Review in COPD. Vol. 81, *Drugs*. Adis; 2021. p. 1411–22.

- Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R. Safety of long-acting β -agonists: Urgent need to clear the air remains. Vol. 33, *European Respiratory Journal*. 2009. p. 3–5.
- [14] Patel S, Dickinson S, Morris K, Ashdown HF, Chalmers JD. A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients. *NPJ Prim Care Respir Med*. 2022 Dec 1;32(1)..
- [15] Billington CK, Penn RB, Hall IP. β_2 Agonists. In: *Handbook of Experimental Pharmacology*. Springer New York LLC; 2016. p. 23–40.
- [16] Radovanovic D, Santus P, Blasi F, Mantero M. The evidence on tiotropium bromide in asthma: From the rationale to the bedside. Vol. 12, *Multidisciplinary Respiratory Medicine*. BioMed Central Ltd; 2017.
- [17] Montuschi P, Ciabattini G. Bronchodilating drugs for chronic obstructive pulmonary disease: Current status and future trends. Vol. 58, *Journal of Medicinal Chemistry*. American Chemical Society; 2015. p. 4131–64.
- [18] Halpin DMG. Tiotropium in asthma: What is the evidence and how does it fit in? Vol. 9, *World Allergy Organization Journal*. BioMed Central Ltd; 2016.
- [19] Baan EJ, Hoeve CE, de Ridder M, Demoen L, Lahousse L, Brusselle GG, et al. The ALPACA study: (In)Appropriate LAMA prescribing in asthma: A cohort analysis. *Pulm Pharmacol Ther*. 2021.1;71.
- [20] Marques L, Vale N. Salbutamol in the Management of Asthma: A Review. Vol. 23, *International journal of molecular sciences*. NLM (Medline); 2022.
- [21] Barjaktarevic I, Kaner R, Buhr RG, Cooper CB. Bronchodilator responsiveness or reversibility in asthma and COPD - A need for clarity. Vol. 13, *International Journal of COPD*. Dove Medical Press Ltd.; 2018. p. 3511–3.
- [22] Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. *Pharmacol Rev*. 2020 Jan 1;72(1):218–52.
- [23] Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Vol. 77, *Allergy: European Journal of Allergy and Clinical Immunology*. John Wiley and Sons Inc; 2022. p. 1105–13.
- [24] Singh D, Garcia G, Maneechotesuwan K, Daley-Yates P, Irusen E, Aggarwal B, et al. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid

Prescribing and Dosing Regimens in Asthma Management. Vol. 39, Advances in Therapy. Adis; 2022. p. 1895–914.

[25] Papi A. A new combination therapy for asthma: Bridging the gap between effectiveness in trials and clinical practice? Respir Med. 2012;106.

[26] Hravank, M et al. Symptom Expression in Coronary Heart Disease and Revascularization Recommendations for Black and White Patients. American Journal of Public Health. 2007. p. 1701-1708.

[27] Donohue, JF et al. Efficacy and Safety of Ipratropium Bromide/Albuterol Compared with Albuterol in Patients with Moderate to Severe Asthma: a Randomized Controlled Trial. Pulmonary Medicine. 2016. 16(65).

[28] Ullah, MU et al. Role of Tiotropium as Step Up Therapy for Asthma. Journal of Rawalpindi Medical College (JRMC). 2013. 17(2). Pp 169-171.

[29] Lorensia A, Ikawati Z, Andayani TM, Maranatha D. Comparison of Improvement in Peak Expiratory Flow Values Using Aminophylline and Salbutamol in Asthma Exacerbations. Indonesia Journal Chest. 2018 . 5(2).

Tables and Figures

Figure 1: Prevalence of drug administration routes





Figure 2: Prevalence receiving monotherapy or combination therapy



Gmail

Search: riska

Active

SMART UNIVERSITY

Compose

Inbox 1,607

Starred

Snoozed

Important

Sent

Drafts 7

Categories

More

Labels

Follow up

Misc

Priority

[ICPHS 2022] Reminder Article Proof & APC Payment External

ICPHS 2022 <scicommicphs2022@gmail.com> to me

Mon, Feb 27, 1:11PM

Article ID: ICPHS-29

Article Title : Patterns of bronchodilator therapy in asthmatic outpatients

Dear Author,

We would like to remind you regarding the article proof and article processing charge payment.

You can download a PDF version of your article as attached in this email. As you are reviewing the proofs, please keep in mind the following:

- This is the only set of proofs you will see prior to publication.
- Only errors introduced during production process or that directly compromise the scientific integrity of the paper may be corrected.
- Any changes that contradict journal style will not be made.
- Any changes to scientific content (including figures) will require editorial review and approval.

Gmail

Search: riska

Active

SMART UNIVERSITY

Compose

Inbox 1,607

Starred

Snoozed

Important

Sent

Drafts 7

Categories

More

Labels

Follow up

Misc

Priority

• Any changes to scientific content (including figures) will require editorial review and approval.

Please check the author/editor names very carefully to ensure correct spelling, correct sequence of given and family names and that the given and family names have been correctly designated (NB the family name is highlighted in blue).

Please submit your corrections within a working day (or the sooner the better) and make sure you fill out your response to any AUTHOR QUERIES raised during typesetting. Without your response to these queries, we will not be able to continue with the processing of your article for Online Publication.

We also would like to inform you that you now need to make a payment of article processing charge (APC) with the details as follows:

Account holder: Kholis Amalia
 Bank Name: Mandiri
 Account Number: 1410011071388
 SWIFT Code: BMRIIDJA
 Amount outstanding: IDR 7,000,000

After the payment, please send us the proof of payment by email.

Should you encounter difficulties with the proofs, please contact us.

Compose

Inbox 1,607

Starred

Snoozed

Important

Sent

Drafts 7

Categories

More

Labels +

Follow up

Misc

Priority

Navigation icons and page number (2 of 8)

After the payment, please send us the proof of payment by email.

Should you encounter difficulties with the proofs, please contact us.

Thank you very much.

Sincerely yours,

GUEST EDITORS

Tutik Sri Wahyuni

Andang Miatmoko

One attachment • Scanned by Gmail

